Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biweekly Pemetrexed and Gemcitabine in Metastatic Breast Cancer
NCT00191347Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed and gemcitabine in breast cancer, sponsored by Eli Lilly and Company. Primary endpoint: Objective Tumor Response Rate. Started Oct 2004; status: completed.
02
Drugs
pemetrexedgemcitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00191347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00191347.